Contineum Therapeutics (CTNM) awards director 19,000-share stock option grant
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Contineum Therapeutics director Olivia C. Ware received a grant of stock options for 19,000 shares of Class A common stock. The options have an exercise price of $14.19 per share and were issued under the 2024 Equity Incentive Plan as part of the non-employee director compensation program. They vest in full on the earlier of June 26, 2027 or the next regular annual stockholder meeting, assuming continuous board service.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Ware Olivia C
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 19,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 19,000 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
Options granted: 19,000 shares
Exercise price: $14.19 per share
Expiration date: June 25, 2036
+2 more
5 metrics
Options granted
19,000 shares
Stock Option (right to buy) for Class A Common Stock
Exercise price
$14.19 per share
Conversion/exercise price of granted options
Expiration date
June 25, 2036
Option term end date
Shares underlying options
19,000 shares
Class A Common Stock underlying this grant
Vesting date trigger
June 26, 2027 or next annual meeting
Options vest in full on earlier of these dates
Key Terms
2024 Equity Incentive Plan, Non-Employee Director Compensation Program, stock option, vest in full, +1 more
5 terms
2024 Equity Incentive Plan financial
"Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program"
Non-Employee Director Compensation Program financial
"pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting"
stock option financial
"will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
vest in full financial
"Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant"
continuous service financial
"or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service."
FAQ
What insider transaction did Contineum Therapeutics (CTNM) report for Olivia C. Ware?
Contineum Therapeutics reported that director Olivia C. Ware received a grant of stock options for 19,000 shares of Class A common stock. The award is part of the company’s non-employee director compensation and reflects equity-based board remuneration rather than an open-market share purchase.
How large is Olivia C. Ware’s stock option grant at Contineum Therapeutics (CTNM)?
Olivia C. Ware was granted options covering 19,000 shares of Contineum Therapeutics Class A common stock. This grant represents her full automatic annual award under the company’s non-employee director compensation program following the regular annual meeting of stockholders.
What is the exercise price and term of the new CTNM stock options?
The granted stock options have an exercise price of $14.19 per share and expire on June 25, 2036. This gives the director a long-term right to purchase shares at that price once the options are fully vested, subject to continued service conditions.
When do Olivia C. Ware’s Contineum Therapeutics options vest?
The options will vest in full on the earlier of June 26, 2027 or the next regular annual stockholder meeting. Vesting is conditioned on Olivia C. Ware’s continuous service as a non-employee director on Contineum Therapeutics’ board through the applicable vesting date.
Under what plan were the new CTNM stock options granted?
The options were granted under Contineum Therapeutics’ 2024 Equity Incentive Plan, pursuant to its Non-Employee Director Compensation Program. This program provides that each continuing non-employee director automatically receives an annual stock option grant following the regular annual meeting of stockholders.